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ABSTRACT 
Objective  We determined the overall effects of microRNA-21 and Interleukin-6 on 
development  of  heart  failure  by  aggregating  literature  and  subjecting  studies 
meeting the inclusion and exclusion criteria to statistical meta-analysis. 
 
Background    MicroRNA’s  are  short  regulatory  RNA’s  that  act  as  negative 
regulators of gene expression by inhibiting mRNA translation or by promoting 
mRNA  degradation.  Experimental  evidence  is  rapidly  accumulating,  which 
demonstrates that microRNA’s constitute a new mode of governing pathophysiological mechanisms in cardiac 
hypertrophy and heart failure. 
Inflammatory activation with increased serum cytokine levels has been described as an important factor in the 
progression of the syndrome of chronic heart failure. In multifactorial analysis, elevated levels of interleukin-6 
have been identified as the prognostic heart failure marker. 
 
Materials and Methods  Original research papers were gathered from Tongji medical college library resources 
and  online  data  bases.  The  papers  were  screened  and  coded;  those  meeting  the  inclusion  and  exclusion 
criterion were subjected to meta-analysis, using Cohen’s d test to determine the effect size of each study. 
 
Results  In microRNA-21 study six studies with 6 effect sizes met the stringent inclusion and exclusion criteria. 
The overall mean effect of microRNA-21 from animal experiment on development of heart failure was highly 
significant (d=+1.36). The fail safe number associated with overall effect of microRNA-21 on development of 
heart  failure  in  animals  was  76,  a  high  number  representing  the  number  of  additional  studies  in  which 
microRNA-21 has negative or no effect on development of Heart failure required to negate the overall large 
effect size of +1.36. 
 
In interleukin-6 study seven studies with 7 effect sizes met the inclusion and exclusion criteria. The mean 
effect of interleukin-6 on development of heart failure from human studies was highly significant (d=+1.41) as 
well as in animal experiments (d=+1.40).  The fail safe number associated with overall effect of interleukin-6 on 
development of heart failure in human was 65 while in animal 26, a high number representing the number of 
additional studies required to negate the overall effect size of +1.4. 
 
Conclusion  We conclude that both microRNA-21 and interleukin-6 has positive effect on the development of 
heart failure. 
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INTRODUCTION 
Definition:    Heart  failure  is  a  complex  syndrome, 
resulting  from  structural  or  functional  cardiac 
disorder that impairs the ability of the cardiac pump 
to support a physiological circulation
 29. 
 
Heart  failure  is  a  worldwide  problem;  and  has 
become an increasingly frequent reason for hospital 
admissions  during  the  last  2  decades  and  clearly 
represents  a  major  health  problem.  The  most 
common  conditions  predating  its  onset  include 
Hypertension  and  coronary  heart  disease,  diabetes 
mellitus is also associated with increased risk of heart 
failure. 
 
Heart  failure  is  the  fastest  growing  clinical  cardiac 
disease entity in the United States, affecting 2% of 
the  population.  Furthermore  underdeveloped 
countries  urbanize  and  become  more  affluent,  the 
rate of heart failure increase in concordance with the 
rates of diabetes mellitus and hypertension, a more 
processed diet and a more sedentarily lifestyle
31. This 
was  illustrated  in  a  population  in  Soweto,  South 
Africa,  as  the  community  transformed  into  a  more 
urban and westernized city, an increase in diabetes 
mellitus and hypertension was met with an increase 
in rate of heart failure.    
 
In  China  according  to  the  report  released  by  the 
China  National  Center  for  Cardiovascular  Disease, 
based on the survey in 2002, there are 160 million 
patients with dyslipidemia, 20 million patients with 
diabetes  mellitus,  200  million  overweight  and  60 
million  obese  patients,  and  350  million  smokers  in 
mainland  China.  The  prevalence  of  heart  failure  in 
China  is  0.9%  of  population  (5.8million  people).  In 
which Male is 0.7%, and in female is 1%. And affects 
people of the age >65years (6-10%). Affecting urban 
(1.4%) more than rural (0.5%), moreover it affects the 
north (1.1%) more than the south (0.8%). Mortality 
from heart failure has increased six times for the last 
40 years
 30. 
 
Diseases of the cardiovascular system represent the 
primary  cause  of  human  morbidity  and  mortality 
underscoring the need for innovative new therapies 
and diagnostics for heart disease 
18. 
 
Cardiovascular  diseases  are  currently  the  leading 
cause  of  death  and  permanent  disability  in  the 
developed countries and looks to set to become the 
leading cause of death worldwide by 2020. In 2000, 
cardiovascular  diseases  were  responsible  for  16.7 
million  deaths  representing  30.9%  of  all  causes  of 
death.  More  than  40%  of  all  causes  in  developed 
countries  and  more  than  25%  in  developing 
countries
30.  
 
Thus it is justifiable to study more on heart failure 
particularly  on  expression  micro  RNA’s  which  are 
contributing  factors  in  its  cause  and  interleukin-6 
which  may  plays  a  great  role  as  a  prognostic 
indicator,  furthermore  the  research  results  will 
facilitate  to  emphasize  the  existing  knowledge 
regarding  expression  of  Micro  RNA-21  and 
interleukin-6 in relation to heart failure.  
 
MATERIALS AND METHODS  
Subjects and design 
Original research papers, investigating the effects of 
microRNA-21 and interleukin-6 on development of 
heart failure, were gathered and used for this study. 
The papers were sought and obtained from Tongji 
medical college library sources and online data bases, 
including Nature, American heart association, and 
European society of cardiology, American college of 
physicians and American college of cardiology and 
Pubmed. Search terms used include microRNA-21, 
effect of microRNA-21 on heart failure, microRNA-21 
and myocardial hypertrophy, micro-RNA-21 and 
myocardial fibrosis, interleukin-6, effect of interleukin-6 
on heart failure and interleukin-6 and myocardial 
hypertrophy. The additional secondary sources of 
information include articles from aforementioned 
sources, internet web pages, and pertinent papers 
published in journeys that were not found from any 
of the above data bases. 
Inclusion criteria: 
  Animal experiments and Human clinical 
studies 
  Journal published between January 1997 to 
January 2012 
  Title: microRNA-21 and interleukin-6 in 
relation with heart failure  
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Exclusion criteria: 
  The article that did not present new data or 
only presented qualitative information 
  If sufficient information to compute effect 
sizes could not be obtained from the article 
  Journals published before January 1997 and 
beyond January 2012 
  microRNA’s other than microRNA-21 and 
Cytokines other than interleukin-6 
 
Data Extraction 
Data were extracted for study title and year, human 
clinical studies and animal experiments. Data were 
extracted by one of the authors and verified by 
another author. Table 1 and 2 shows the studies used 
in the present meta-analysis. The overall result of 
each study was transformed into a standardized 
effect size statistic using Cohen’s‘d’ formula.  
 
Data analysis 
Calculation of Cohen’s d: effect sizes were calculated 
using the formulae for determining Cohen’s‘d’. 
According to wolf, Cohen’s‘d’ may be defined as the 
standardized difference between the means of the 
experimental group and the comparison group. This 
definition and Cohen’s classification of effect sizes 
were applied to each study included in our meta-
analysis. According to Cohen, the values of 0.2, 0.5 
and 0.8 indicate a small, medium and large average 
effect, respectively. 
 
Conceptually Cohen’s statistic may be expressed as 
follows: 
    d= X1 – X2 
             SDcomparison 
Where; 
d = is the effect size 
X1= is the mean of microRNA-21 or interleukin-6 
X2= is the mean of the comparison group 
SD= is the standard deviation of the comparison 
group 
 
The effect size (d) was assigned a positive or negative 
value depending on the outcome of the study. For 
example, positive values were assigned to studies 
whose results were positive, that is, indicated that 
microRNA-21 or interleukin-6 is up regulated in heart 
failure. Negative values were assigned to studies that 
showed negative effect on development of heart 
failure that means microRNA-21 or interleukin-6 
down regulated or no change in levels in heart failure. 
After calculating the effect size of each study 
independently, the mean overall effect size was 
calculated by summing all the effect sizes and 
dividing by the total number of effect using the 
following formula: 
  daverage = ∑ d  
       N 
Where; 
daverage = is mean effect size 
∑ d = is the sum of the effect sizes, and 
N= is total number of effect sizes calculated and 
used. 
 
Calculation of failsafe number 
Given the likelihood that we did not obtain every 
study that ever examined the effects of microRNA-21 
and interleukin-6 on development of heart failure, a 
failsafe number (Nfs) was calculated. The failsafe 
number reveals the number of additional studies with 
effect sizes below a set criterion value that would 
have to be included in the meta-analysis in order to 
change the outcome of the study. 
  
We used 0.10 as the criterion, a number that is less 
than the small effect size of 0.2 suggested by Cohen. 
The following formula was used to calculate the 
failsafe number: 
    Nfs = N(đ-dc) 
                                                dc 
Where: 
  Nfs = is the failsafe number 
  N= is the number of studies in the meta-
analysis 
  đ = is the average effect size of all studies 
  dc = is the criterion value 
 
3.2 STATISTICAL ANALYSIS 
Statistical  analysis  was  performed  by  using  Meta-
analyst  software  beta  and  SAS  software.  All  the 
data was presented as mean ±SD and all P value was 
sided  with  significant  level  of  α=0.05.    And  the 
significance difference of micro RNA or interleukin-6  
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levels  between  case  and  control  subjects  was 
analyzed accordingly. 
 
3.3 ETHICAL CONSIDERATION 
Ethical principles were followed; in this research were 
the  Tongji  medical  college  of  HUST  Ethical  review 
committee approved this research.  
 
RESULTS 
Our  literature  search  revealed  several  studies  that 
examined  the  effects  of  microRNA-21  and 
interleukin-6, 26 studies for microRNA-21 and 22 for 
interleukin-6, but the final set of papers from which 
the effect sizes could be calculated was just 6 and 7 
for microRNA-21 and interleukin-6 respectively. 
 
Insufficient data with which to calculate effect size 
and/or  inadequate  reporting  of  microRNA-
21/interleukin-6 were the major reasons that so many 
studies  were  not  included  in  the  meta-analysis.  In 
addition,  there  were  several  studies  in  which  data 
were  summarized  in  the  form  of  illustrations  and 
graphs from which it was not possible to extrapolate 
the data needed to compute Cohen’s d. The overall 
mean effect size (Cohen’s d and hedge’s g) plus the p-
values and I
2 from the studies were as follows: 
 
  Table 1 
Study  Cohen’s d  Hedge’s g  p-value  I
2 
MicroRNA-21  1.36  1.09  0.008  68.23 
Interleukin-6-
animal 
1.40  15  0.004  82 
Interleukin-6-
human 
1.41  2.33  0.000  96 
 
Indicating that both MicroRNA-21 and interleukin-6 
have  positive  effects  on  the  development  of  heart 
failure, I used hedge’s g for more clarification of the 
effect measure because it has additional advantage 
of  providing  accurate  estimate  and  stable  measure 
with no bias. An initial test of homogeneity indicated 
heterogeneity  across  the  studies  with  the  p-values 
lower than 0.05 and high I
2 as indicated in the table 
above  in  Table  1,  with  medium  heterogeneity  in 
microRNA-21 (68.23) and high heterogeneity in both 
interleukin-6 studies 82 and 96 in animal and human 
studies  respectively.  Furthermore  the  fail  safe 
number was calculated for both studies, and it was 76 
for MicroRNA-21, meaning that 76 additional studies 
in  which  microRNA-21  had  little  or  no  effect  on 
development  of  heart  failure  would  be  needed  to 
negate the large positive effect of microRNA-21 of 
this  meta-analysis.  In  interleukin-6,  the  fail  safe 
number  was  26  in  animal  experiment  and  65  in 
human  studies  meaning  that  26  and  65  additional 
studies in animal and human studies respectively in 
which  interleukin-6  had  little  or  no  effect  on 
development  of  heart  failure,  would  be  needed  to 
negate the large positive effect of interleukin-6. The 
statistical significance test was done with p-values in 
both studies being below 0.05, P-value of 0.008 for 
microRNA-21 study, P-values of 0.004 and 0.000 in 
interleukin-6 animal and human studies as shown in 
Table  1,  indicating  a  statistical  significance  in  this 
meta-analysis. 
 
Despite the above fact all the studies favors the test, 
indicating the distribution of their confidence interval 
on  the  right  side  above  zero.  Moreover  the  95% 
confidence intervals in the microRNA-21 study were 
distributed as follows; 4 studies had medium effect at 
a certain confidence interval 0.5 and large effect at 
1.0  confidence  interval  in  1  study,  furthermore  the 
95% confidence interval for the overall microRNA-21 
meta-analysis is between 0.52-0.56, and at 0.54 point 
estimate  there  is  no  difference  with  no  effect  as 
shown in figure 1, in addition to the above fact the 
95% confidence intervals in the interleukin-6 human 
studies lie between 0.5-0.6 confidence interval, and 
the overall interleukin-6 human study meta-analysis 
is between 0.53-0.57, and at 0.55 point estimate there 
is no difference with no effect as shown in figure 2, 
furthermore the confidence interval in interleukin 6 
animal study lie between 0.51-0.56, and at 0.52 point 
estimate there is no difference with no effect. In both  
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studies  MicroRNA-21  and  interleukin-6  animal 
experiments there was symmetry of the effects in the 
studies indicating no bias, as shown in the figures 5 
and 6, despite the above fact there was asymmetry in 
the effect of interleukin-6 human studies indicating 
publication bias, although the fail safe number was 
65 studies. 
 
In summary the results indicate that both microRNA-
21  and  interleukin-6  have  positive  effect  on  the 
development of heart failure proving my hypothesis.  
 
 
 
 
 
 
 
Figure 1 Showing how the 95% confidence intervals of microRNA-21 study are distributed differently within the 
forest plot. Indicating how the study is significant as there all above zero 
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Figure 2 Showing how the 95% confidence intervals of interleukin-6 human study are distributed differently within 
the forest plot. Indicating how the study is significant as there all above zero 
 
 
 
Figure 3 Showing how the 95% confidence intervals of interleukin-6 human study are distributed differently within 
the forest plot. Indicating how the study is significant as there all above zero  
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Figure 4 A funnel plot of studies with the positive effect of microRNA-21 symmetrical, suggesting the absence of 
bias 
 
 
 
Figure 5 A funnel plot of interleukin-6 human studies with the positive effects asymmetrical, suggesting publication 
bias 
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Figure 6 A funnel plot of interleukin-6 animal studies with the positive effects symmetrical, suggesting absence of 
bias 
 
DISCUSSION 
Overall,  our  findings  show  that  both  microRNA-21 
and  interleukin-6  have  a  positive  effect  in 
development  of  heart  failure.  This  finding  is 
consistent  with  several  reports  that  indicate  that 
both  microRNA-21  and  interleukin-6  contribute  to 
the  development  of  heart  failure  by  fueling 
myocardial fibrosis, a major change occurring during 
heart failure. 
 
In  this  systematic  review  of  the  effect  of  both 
MicroRNA-21  and  interleukin-6  in  development  of 
heart failure had an excellent effect sizes, (Cohen’s d 
and hedges g) with Cohen’s d of 1.36 and hedge’s g of 
1.09 in microRNA-21 studies, and Cohen’s d of 1.40, 
1.41 and hedge’s g of 15, 2.33 in interleukin-6 animal 
and human studies respectively. Our findings suggest 
that both microRNA-21 and interleukin-6 results can 
be  conclusively  to  have  positive  effects  in 
development of heart failure with their large effect 
sizes. 
 
In  microRNA-21  only  6  animal  experiments  were 
included in this meta-analysis because there were no 
quantitative  data  and  details  to  extract  in  human 
studies  thus microRNA-21  human  studies  were  not 
included in this meta-analysis. In interleukin-6 there 
were 5-human studies and 2 animal studies included 
in this meta-analysis. 
 
Our review has limitations we only included English 
language studies. The funnel plot for the interleukin-
6  human  study  was  asymmetrical  which  suggest 
publication  bias  may  be  present.  Nevertheless,  
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because the fail-safe number was 65 studies we feel 
confident  about  our  findings  because  it  highly 
unlikely  that  there  are  65  additional  unpublished 
studies with no significant findings (no effect).  
 
Perhaps the most important bias of meta-analysis is 
the  expectancy  effect,  Cotton  and  Cook  (1982) 
recommended  early  on  that  the  investigators  of 
meta-analysis explicitly state their personal view with 
regards to the outcome in order to acknowledge and 
possibly avoid expectancy effect. At the outset of our 
review, we were rather critical toward the effect of 
both microRNA-21 and interleukin-6 in development 
of heart failure. We expressed our personal view and 
we were fully prepared to report non-significant or 
only  small  effect  of  both  microRNA-21  and 
interleukin-6. We were surprised to find these effects 
to be rather robust and strong, therefore believe that 
the  expectancy  bias  was  unlikely  to  be  significant 
contributor  to  the  results,  which  generally  support 
the  effects  of  MicroRNA-21  and  Interleukin-6  in 
development of heart failure. 
 
In  conclusion,  currently  available  literature 
demonstrates  that  both  microRNA-21  and 
interleukin-6 have positive effect in development of 
heart failure. And therefore this might be a potential 
breakthrough  in  search  for  the  treatment  of  heart 
failure,  furthermore  even  in  determination  of 
patients  prognosis.  I  believe  there  still  some  more 
researches needed to be done in this field particularly 
in  trying  to  target  or  block  MicroRNA-21  and/or 
Interleukin-6 in heart failure patients, more emphasis 
should be performed in microRNA-21 human studies 
in the future. 
 
Current  literature  still  reveals  the  importance  of 
microRNA-21 in heart failure, in a study of the role for 
microRNA-21  in  atrial  profibrillatory  fibrotic 
remodeling  associated  with  experimental  post-
infarction heart failure by Cardin S, Guasch E, Luo X, 
et al. published in Pub-med in October 2012 where 
they  revealed  myocardial  infarction  induced  heart 
failure  leads  to  atrial  remodeling  in  rats,  and  the 
knockdown  of  atrial  microRNA-21  suppresses  atrial 
fibrosis  implicating  microRNA-21  as  a  potential 
target for molecular intervention designed to prevent 
Atrial  fibrosis.,  despite  the  above  fact  there  was 
another study by Qin Y, Yu Y, et al. which revealed 
over  expression  of  microRNA-21  following  cardiac 
ischemia-reperfusion injury decreased infarcted area 
and  reduced  cell  apoptosis  in  border  area,  which 
improved  heart  function,  hemodynamic  status  and 
inhibited left ventricular remodeling in rats published 
in 2012 in international medical science journal this 
one favoring the over-expression of microRNA-21 in 
ischemia reperfusion injury. 
 
In  summary  the  results  of  this  statistical  meta-
analysis mandate the following conclusions: 
  microRNA-21  has  a  positive  effect  in 
development of heart failure 
  interleukin-6  has  a  positive  effect  in 
development of heart failure 
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